GlaxoSmithKline Pharmaceuticals Limited (GSK) revenue from operations for Q2 FY25 grew by 5% to cross Rs. 1,000 crores whereas Profit After Tax (PAT) for the quarter Rs. 249 crores grew by 15%.

For the half year ended 30th September 2024, the company delivered Rs. 1,811 crore revenue from operations recording a growth of 7%. Profit before exceptional items and tax for the half year at Rs. 583 crore improved by 27% with EBITDA margins at 30%.

The Board of Directors at its meeting held on 29th October 2024 declared a special interim dividend of Rs. 12 per equity share of face value of Rs. 10 each.

While key brands held their market share and continued to stay in line with the respective category performance, the represented market experienced sluggish growth in General Medicines. Augmentin continues to be the No. 1 brand in the overall Indian pharma market and respiratory portfolio led by Nucala and Trelegy continued to gain market share.

The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market. In the Adult Vaccines segment, GSK continues to build on the momentum of its Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted), advancing the Adult Immunisation category in India through innovative go-to-market (GTM) strategies.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, “As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders."

"Our performance reflects our commitment to sustainable growth and innovation. Furthermore, our shingles diseases awareness campaign featuring Amitabh Bachchan has significantly elevated the discussion around Shingles prevention, reinforcing our focus in preventive healthcare in India,” commented Akshikar.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together.